What are the key differences between thrombotic microangiopathy (TMA) and thrombotic thrombocytopenic purpura (TTP), and how should each be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

TMA vs TTP: Key Differences and Management

TTP is a specific subtype of TMA—not a separate entity—defined by severe ADAMTS-13 deficiency (<10%), while TMA is an umbrella term encompassing multiple disorders that share the common pathologic triad of microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis.

Understanding the Relationship

TMA (thrombotic microangiopathy) represents a pathologic syndrome, not a single disease. TTP is one specific cause within the broader TMA category 1, 2. Think of TMA as the clinical presentation (the "what you see") and TTP as one of several underlying etiologies (the "why it's happening").

The TMA Umbrella Includes:

  • TTP (immune or congenital): ADAMTS-13 deficiency <10%
  • Complement-mediated TMA (aHUS): Dysregulated alternative complement pathway
  • STEC-HUS: Shiga toxin-producing E. coli infection
  • Secondary TMAs: Drug-induced, malignancy, transplant, pregnancy, autoimmune disease, malignant hypertension 2, 3

Critical Diagnostic Distinction

Immediate Laboratory Workup When TMA Suspected:

When you see thrombocytopenia + microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin, negative Coombs) + organ dysfunction, you must:

  1. Draw ADAMTS-13 activity and inhibitor levels IMMEDIATELY before any plasma therapy 1, 4
  2. Send stool for Shiga toxin/VTEC if diarrhea present 5
  3. Check complement levels if considering aHUS 5

The Defining Test:

  • ADAMTS-13 activity <10% = TTP (with inhibitor = immune TTP; without = likely congenital TTP) 1
  • ADAMTS-13 activity >10% = NOT TTP; consider other TMA causes 6

Critical pitfall: ADAMTS-13 results take days. While waiting, use clinical scoring systems (PLASMIC score or French score) to assess TTP probability 1, 7. High scores warrant empiric TTP treatment.

Management Algorithms

For Suspected TTP (Before ADAMTS-13 Results):

Start plasma exchange (PE) immediately if clinical suspicion is high—do not wait for ADAMTS-13 confirmation, as TTP is rapidly fatal without treatment 1, 4, 7.

For Confirmed Immune TTP (iTTP):

Triple therapy per 2025 ISTH guidelines 1:

  1. Plasma exchange daily until platelet recovery
  2. Corticosteroids (prednisone 1 mg/kg or equivalent)
  3. Rituximab (375 mg/m² weekly × 4 doses)
  4. Caplacizumab (add to above regimen—blocks VWF-platelet interaction, reduces recurrence, shortens PE duration, and hospital stay) 1, 7

Key point: Start caplacizumab within 3 days of TMA recognition for maximum benefit 7. Monitor for bleeding (11% serious bleeding risk vs 1% placebo, but all resolved) 7.

For Congenital TTP (cTTP) in Remission:

Strong 2025 recommendation: Use recombinant ADAMTS-13 over fresh frozen plasma for prophylaxis 1. If recombinant unavailable, use FFP over watch-and-wait approach 1.

For Non-TTP TMA (ADAMTS-13 >10%):

DO NOT continue plasma exchange—it only benefits TTP and rare aHUS cases 6. Management depends on specific etiology:

  • Complement-mediated TMA (aHUS): Consider complement inhibition (eculizumab/ravulizumab) if genetic mutations confirmed 5, 8
  • STEC-HUS: Supportive care; PE not indicated 2
  • Secondary TMA: Treat underlying cause (stop offending drug, control hypertension, treat infection) 9, 3

Common Diagnostic Pitfalls

  1. Assuming all TMA is TTP: Only ~5-10% of TMA cases are TTP 2. Starting PE for hypertensive emergency-associated TMA or drug-induced TMA wastes resources and delays appropriate treatment 9.

  2. Missing the diagnosis window: Severe thrombocytopenia (usually <30 × 10⁹/L) with hemolysis demands immediate action 1. Neurologic symptoms occur in only 10-20% of cases—their absence doesn't exclude TTP 5.

  3. Waiting for schistocytes: Schistocytes >1% support TMA, but their absence doesn't exclude it due to low test sensitivity 5. Don't delay treatment.

  4. Ignoring ADAMTS-13 in "obvious" secondary TMA: Infections (including dengue), autoimmune disease, and other triggers can precipitate TTP in predisposed individuals 8. Always check ADAMTS-13.

Clinical Presentation Nuances

TTP typically presents with:

  • Severe thrombocytopenia (<30 × 10⁹/L)
  • Microangiopathic hemolysis (elevated LDH, schistocytes, low haptoglobin)
  • Variable organ involvement (neurologic 10-20%, renal common but less severe than aHUS) 1, 5

Complement-mediated TMA (aHUS) typically presents with:

  • Prominent renal failure (more severe than TTP)
  • Less severe thrombocytopenia (often >30 × 10⁹/L)
  • Genetic complement mutations (CD46, CFH, CFI, etc.) 5, 8

Age matters: In children <2 years with TMA, consider STEC-HUS first, then congenital TTP, cobalamin metabolism defects, or DGKE mutations 5, 2. In adults, secondary causes and acquired ADAMTS-13 deficiency predominate 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.